Average adherence to boosted protease inhibitor therapy, rather than the pattern of missed doses, as a predictor of HIV RNA replication.
about
HIV Treatment Adherence, Drug Resistance, Virologic Failure: Evolving ConceptsContemporary issues on the epidemiology and antiretroviral adherence of HIV-infected adolescents in sub-Saharan Africa: a narrative reviewSuper Learner Analysis of Electronic Adherence Data Improves Viral Prediction and May Provide Strategies for Selective HIV RNA Monitoring.Treatment strategies for treatment naïve HIV patients in Germany: evidence from claims data.Using the multiphase optimization strategy (MOST) to optimize an HIV care continuum intervention for vulnerable populations: a study protocol.Pharmacologic boosting of atazanavir in maintenance HIV-1 therapy: the COREYA propensity-score adjusted studyAssociation of first-line and second-line antiretroviral therapy adherence.Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapyBenefits of adherence to psychotropic medications on depressive symptoms and antiretroviral medication adherence among men and women living with HIV/AIDS.Effect of directly observed antiretroviral therapy compared to self-administered antiretroviral therapy on adherence and virological outcomes among HIV-infected prisoners: a randomized controlled pilot study.Survival of AIDS patients treated with traditional chinese medicine in rural central china: a retrospective cohort study, 2004-2012Short communication: Tenofovir diphosphate in dried blood spots as an objective measure of adherence in HIV-infected women.Adherence to extended postpartum antiretrovirals is associated with decreased breast milk HIV-1 transmission.EPICE-HIV: An Epidemiologic Cost-Effectiveness Model for HIV Treatment.Self-reported adherence supports patient preference for the single tablet regimen (STR) in the current cART era.Antiretroviral dynamics determines HIV evolution and predicts therapy outcome.A systematic review of antiretroviral adherence interventions for HIV-infected people who use drugsTenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure.Supporting Treatment Adherence Readiness through Training (START) for patients with HIV on antiretroviral therapy: study protocol for a randomized controlled trial.Adherence and viral suppression among infants and young children initiating protease inhibitor-based antiretroviral therapy.Adherence profiles and therapeutic responses of treatment-naive HIV-infected patients starting boosted atazanavir-based therapy in the ANRS 134-COPHAR 3 trial.Aggregate versus day level association between methamphetamine use and HIV medication non-adherence among gay and bisexual men.Adherence to Antiretroviral Therapy and Virologic Failure: A Meta-AnalysisPatterns of antiretroviral therapy adherence and impact on HIV RNA among patients in North AmericaHigher baseline CD4 cell count predicts treatment interruptions and persistent viremia in patients initiating ARVs in rural UgandaThe choice between a ritonavir-boosted protease inhibitor- and a non-nucleoside reverse transcriptase inhibitor-based regimen for initiation of antiretroviral treatment - results from an observational study in Germany.Levels of adherence required for virologic suppression among newer antiretroviral medications.Unstructured treatment interruption of antiretroviral therapy in clinical practice: a systematic review.Switching to Raltegravir From a Virologically Effective Boosted Protease Inhibitor Regimen: A Comparative Effectiveness Analysis From the French Hospital Database on HIV (FHDH-ANRS CO4).Relationship between ever reporting depressive symptoms and all-cause mortality in a cohort of HIV-infected adults in routine care.A Cost-effectiveness Analysis of Preexposure Prophylaxis for the Prevention of HIV Among Los Angeles County Men Who Have Sex With Men.Adherence to PI-based 2nd line regimens in Cambodia is not simply a question of individual behaviour: the ANRS 12276 2PICAM study.Roles of Medication Responsibility, Executive and Adaptive Functioning in Adherence for Children and Adolescents With Perinatally Acquired HIV.Nonadherence as 4-day Antiretroviral Therapy Interruptions: Do Depression and Race/Ethnicity Matter as Much in the Modern Antiretroviral Therapy Era?Medication persistence of HIV-infected drug users on directly administered antiretroviral therapy.Higher Art Adherence is Associated with Lower Systemic Inflammation in Treatment-Naïve Ugandans Who Achieve Virologic Suppression.Do Persons Living with HIV Continue to Fill Prescriptions for Antiretroviral Drugs during a Gap in Care? Analysis of a Large Commercial Claims Database.Monitoring self-reported adherence to antiretroviral therapy in public HIV care facilities in Brazil: A national cross-sectional study.British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015Measuring Adherence to Antiretroviral Treatment: The Role of Pharmacy Records of Drug Withdrawals
P2860
Q22241321-FD38891C-0F93-4F2F-80DC-D16DD81670A9Q26783160-8E95F57C-FBAD-48A4-82F5-A3953FB16C78Q30944694-97BAF504-23C2-4255-8E0F-44A25B331BE1Q30979260-65CE927C-B99D-4919-A948-9922D36E332AQ33640486-3BAF8BB5-03D5-4EF8-BCAB-54C05D90BED8Q34477917-6AAA63E8-FC5D-453E-AB38-CA2E9A754000Q34801978-3E410E25-0939-49A1-BBB8-C7D420A444C8Q34814795-0906B237-B5F4-422B-A621-E044151F6EAAQ34845860-2F4786DF-80C5-4297-AA62-86CA16E6C424Q35001897-355FBD3F-B45F-43C5-9CBC-4C5A5CD68CF2Q35188327-09AD459F-4267-4845-BBB0-7006F8F7773AQ35230243-F3B3FE62-2C56-4563-8B0F-A2FBE1E638CFQ35423380-0493ACC2-A54F-411D-B557-3B5AECA352FAQ35921909-01BA43B2-0DF1-4BE2-99C6-946A36A37EB2Q36048423-9BBE5E16-CD05-45CA-B58B-05E3911CED8BQ36374300-465B1E8F-7F52-4BCE-9FB4-09FAE66224D5Q36390767-D9CE388E-ED3A-41DA-9911-FF581FE5C81AQ36554980-287E499D-D00E-4D7D-A082-2FF884B3016AQ36725077-4A6121B9-C21E-47C5-A549-92D84C7F840EQ36759507-7F78FAA7-7168-42E9-987F-721C377639CDQ36785804-0533AD7B-6C3C-447A-9DCB-EC53879FD7B2Q36813501-88B715A6-7C31-402C-915E-C90FB2F27745Q36822464-E5A69AF1-842C-4D8D-A815-BF9F417F4CDFQ36848472-B68EA47D-A765-440E-8C81-3C363A9071E0Q36964952-1DED8021-734C-42DE-927C-789443338373Q37547161-B556A2B8-1233-494D-8AF0-5D3C475BB5BCQ37850889-198C196E-3295-4EBA-95EC-B671BD39702DQ37896165-50810109-FC11-4162-8F40-BDED92346041Q38406037-3135AAA7-C3EC-40BA-B8E8-6D9134703577Q38937435-BD485E96-7A54-43FB-BC75-23CAA8B63F0FQ39456029-0C560979-C78C-4749-83F7-2F736E277803Q40041832-07E520DD-6456-4870-B8DC-CE5860A55206Q40134418-0140185E-1618-4C68-BBFC-32752A564221Q42674946-273F4625-E563-4318-9463-E4C170687FE2Q44147560-F50AEEA5-3574-4EAE-B607-D6482CA67C8FQ47551904-CD48179B-8AF2-4B20-985C-03D99E7E00CCQ50129820-75ABD1C2-C41E-4FF5-9915-E0B2B0491308Q55210131-D4D09BBC-6523-49A7-BAF4-631249DEB672Q57180790-FFAA70AF-EE09-44F8-ABD8-F8D8717EE959Q58864351-A67A5C3D-29DE-41AB-8DE8-50772E5357BF
P2860
Average adherence to boosted protease inhibitor therapy, rather than the pattern of missed doses, as a predictor of HIV RNA replication.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Average adherence to boosted p ...... dictor of HIV RNA replication.
@ast
Average adherence to boosted p ...... dictor of HIV RNA replication.
@en
type
label
Average adherence to boosted p ...... dictor of HIV RNA replication.
@ast
Average adherence to boosted p ...... dictor of HIV RNA replication.
@en
prefLabel
Average adherence to boosted p ...... dictor of HIV RNA replication.
@ast
Average adherence to boosted p ...... dictor of HIV RNA replication.
@en
P2093
P2860
P356
P1476
Average adherence to boosted p ...... dictor of HIV RNA replication.
@en
P2093
Arnaud de la Blanchardière
ESPOIR and REACH study groups
Frédéric Lucht
Jean-Jacques Dutheil
Kathleen Ragland
Philippe Perré
Renaud Verdon
Sylvie Dargère
Yazdan Yazdanpanah
P2860
P304
P356
10.1086/651419
P407
P577
2010-04-01T00:00:00Z